Severe Acute Respiratory Syndrome Clinical Trial
— proneOfficial title:
Effect of Early Implementation of Prone Positioning Among Critically Ill Patients Admitted With Acute Respiratory Distress Syndrome During the COVID-19 Time: A Comparative Retrospective Observational Study
NCT number | NCT06287554 |
Other study ID # | 404/2024 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | March 4, 2020 |
Est. completion date | April 20, 2022 |
Verified date | February 2024 |
Source | Zulekha Hospitals |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational [Patient Registry] |
Background and objective: The ramifications of early lung protective measures and prone positioning on the ICU length of stay rates of participants admitted to the ICU with acute respiratory distress syndrome amid the COVID-19 pandemic constitute a pivotal examination. The study aims to identify the effect of early prone positioning on the length of stay, discharge rate, and number of tracheostomized patients in the ICU.
Status | Completed |
Enrollment | 70 |
Est. completion date | April 20, 2022 |
Est. primary completion date | April 20, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: - All patients of both sexes. - Aged from 18 to 70 years. - Body Mass Index (BMI) from 25 to 35 kg/m2. - Critically ill due to ARDS resulting from COVID-19 pneumonia. Exclusion Criteria: - Patients who spent more than 24 hours on mechanical ventilators before enrolment in the study. - Patients who died within the first 24 hours of presentation. - Patients with advanced cancer. - Pregnant patients. |
Country | Name | City | State |
---|---|---|---|
Egypt | Al-Azhar faculty of medicine | Cairo |
Lead Sponsor | Collaborator |
---|---|
Zulekha Hospitals | Al-Azhar University |
Egypt,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of discharged patients | Number of discharged patients | 26 MONTHS | |
Secondary | The total length of stay | The total length of stay | 26 MONTHS | |
Secondary | ICU length of stay | ICU length of stay | 26 MONTHS | |
Secondary | Patients who underwent tracheostomy procedures | Patients who underwent tracheostomy procedures | 26 MONTHS |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04542915 -
COVID-19-Related Health and Practices Among Dental Hygienists
|
||
Completed |
NCT04515147 -
A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19
|
Phase 2 | |
Recruiting |
NCT04480333 -
Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831
|
Phase 1 | |
Completed |
NCT04402957 -
LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)
|
Phase 2 | |
Withdrawn |
NCT04838847 -
A Study to Evaluate the Immunogenicity and Safety of the SARS-CoV-2 mRNA Vaccine CVnCoV in Elderly Adults Compared to Younger Adults for COVID-19
|
Phase 3 | |
Not yet recruiting |
NCT04386070 -
Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19
|
Phase 3 | |
Withdrawn |
NCT00073086 -
Evaluation and Treatment of Severe Acute Respiratory Syndrome (SARS)
|
N/A | |
Active, not recruiting |
NCT04527432 -
COVID-19 Health Professional Impact Study
|
N/A | |
Completed |
NCT00215826 -
Study of Alferon® LDO (Low Dose Oral) in Normal Volunteers
|
Phase 2 | |
Completed |
NCT04366934 -
Study of the Pathogenesis of Olfactory Disorders in COVID-19
|
||
Completed |
NCT04376684 -
Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease
|
Phase 2 | |
Completed |
NCT04402060 -
A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19
|
Phase 1/Phase 2 | |
Completed |
NCT04395144 -
COVid-19: Awake Proning and High-flow Nasal Cannula in respiratorY DistrEss
|
N/A | |
Completed |
NCT04357730 -
Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection
|
Phase 2 | |
Completed |
NCT04425213 -
Obesity and Mortality of Critically Ill Patients With COVID-19
|
||
Completed |
NCT04425863 -
Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19
|
||
Completed |
NCT04328129 -
Household Transmission Investigation Study for COVID-19 in Tropical Regions
|
N/A | |
Completed |
NCT04602351 -
Communication in ICU During COVID-19
|
||
Completed |
NCT03225807 -
Implementation of Lung Protective Ventilation in Patients With Acute Respiratory Failure
|
||
Recruiting |
NCT04381819 -
Norwegian SARS-CoV-2 Study - Virological, Clinical and Immunological Characterisation of COVID-19
|